Report Overview
Global AI-Driven Retinal Screening Device Market size is expected to be worth around US$ 7.1 Billion by 2035 from US$ 2.2 Billion in 2025, growing at a CAGR of 12.6% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 41.3% share with a revenue of US$ 0.9 Billion.
The global AI-Driven Retinal Screening Device Market is witnessing steady growth as healthcare providers increasingly adopt artificial intelligence to improve the early detection of retinal diseases.
These devices combine advanced retinal imaging systems with AI-powered software to automatically analyze retinal images and identify conditions such as diabetic retinopathy, glaucoma, age-related macular degeneration, and other vision-threatening disorders. The technology enables faster, more accurate screening while reducing the workload on ophthalmologists and improving access to eye care, particularly in remote and underserved communities.
The growing prevalence of diabetes, an aging global population, and the increasing incidence of preventable blindness are key factors supporting market expansion.
Hospitals, specialty eye clinics, and diagnostic centers are integrating AI-enabled retinal screening into routine eye examinations to enhance diagnostic efficiency and enable timely treatment.
Advances in cloud computing, portable retinal cameras, and teleophthalmology platforms are further improving the accessibility and scalability of these solutions.
According to recent market estimates, the global AI-Driven Retinal Screening Device Market is projected to grow from US$ 2.2 Billion in 2025 to approximately US$ 7.1 Billion by 2035, registering a compound annual growth rate (CAGR) of 12.6% during the forecast period from 2026 to 2035.
Click here for more information: https://market.us/report/ai-driven-retinal-screening-device-market/
Key Takeaways
- Market Size: The global AI-Driven Retinal Screening Device Market was valued at US$ 2.2 Billion in 2025 and is projected to reach US$ 7.1 Billion by 2035.
- Market Growth: The market is anticipated to expand at a CAGR of 12.6% during the forecast period from 2026 to 2035.
- By Component: The software segment led the market, accounting for 52.7% of the global market share in 2025.
- By Type: Diabetic retinopathy screening devices emerged as the leading segment, capturing 45.8% of the market share in 2025.
- By End User: Hospitals held the largest share of the market, representing 39.4% in 2025.
- By Region: North America dominated the global market in 2025, securing 41.3% of the market share and generating US$ 0.9 Billion in revenue.
Key Market Segments
- By Component
- Hardware
- Software
- By Type
- Diabetic Retinopathy Screening Devices
- Glaucoma Detection Devices
- Age-related Macular Degeneration (AMD) Screening Devices
- Others
- By End-User
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
- Others
Market Key Players
- Eyenuk, Inc.
- Digital Diagnostics, Inc.
- Retina-AI Health, Inc.
- AEYE Health, Inc.
- Optomed plc
- Verily Life Sciences (a Google company)
- Forus Health Pvt. Ltd.
- Medios (RetinaLyze System)
- iHealthScreen Inc.
- AiDx Medical Inc.
- DeepMind (Google-owned)
- Visulytix Ltd.
- Guangxi Realway Medical
- Novasight
- PlenOptika, Inc.
- Others
Market Dynamics
Driver
The increasing prevalence of diabetes is a major driver for the AI-Driven Retinal Screening Device Market. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20–79 years were living with diabetes in 2024, and this number is projected to exceed 850 million by 2050. Diabetes significantly raises the risk of diabetic retinopathy, one of the leading causes of preventable blindness among working-age adults. The U.S.
Centers for Disease Control and Prevention (CDC) estimates that nearly 9.6 million Americans have diabetic retinopathy, with millions more at risk as diabetes rates continue to rise. AI-powered retinal screening devices help detect retinal abnormalities within minutes, improving early diagnosis and reducing the burden on ophthalmologists.
The National Eye Institute (NEI) states that early detection and timely treatment can reduce the risk of severe vision loss by up to 95% in people with diabetic retinopathy. Governments and healthcare providers are expanding diabetic eye screening programs, increasing the adoption of AI-assisted diagnostic technologies. These developments support faster, scalable, and cost-effective retinal screening, driving sustained market demand worldwide.
Trend
A key trend shaping the AI-Driven Retinal Screening Device Market is the growing integration of artificial intelligence into routine ophthalmic screening services. Healthcare systems are increasingly adopting AI algorithms to improve diagnostic accuracy, reduce waiting times, and expand screening coverage, particularly in underserved regions.
The World Health Organization (WHO) estimates that at least 2.2 billion people globally have a vision impairment or blindness, with at least 1 billion cases being preventable or yet to be addressed. AI-enabled retinal imaging supports large-scale screening by automatically identifying diabetic retinopathy, glaucoma, and age-related macular degeneration with high accuracy.
The U.S. Food and Drug Administration (FDA) has authorized multiple AI-based ophthalmic diagnostic systems for autonomous disease detection, reflecting growing regulatory confidence in these technologies. Additionally, teleophthalmology programs supported by AI are becoming more common in rural healthcare settings, where access to eye specialists remains limited.
Cloud-based image analysis, electronic health record integration, and portable retinal cameras are further enhancing screening efficiency. These technological advances continue to improve accessibility, workflow, and clinical decision-making across healthcare systems.
Restraint
Despite rapid technological progress, limited access to retinal imaging equipment and digital healthcare infrastructure remains a significant restraint for the AI-Driven Retinal Screening Device Market.
AI systems depend on high-quality retinal images for accurate disease detection, yet many low- and middle-income countries face shortages of retinal cameras, trained technicians, and reliable internet connectivity.
According to the World Health Organization (WHO), more than 90% of people with vision impairment live in low- and middle-income countries where access to specialized eye care remains insufficient. The International Agency for the Prevention of Blindness (IAPB) also highlights major disparities in eye care resources, particularly in rural and remote communities. Initial investments in AI-compatible imaging devices, software integration, cybersecurity, and staff training can be challenging for smaller hospitals and primary healthcare centers with limited budgets.
Variations in image quality may also reduce AI performance, requiring manual review by specialists. Furthermore, regulatory compliance, patient data protection, and interoperability with hospital information systems create additional implementation challenges that may slow adoption across developing healthcare markets.
Opportunity
The expansion of community healthcare services presents a significant opportunity for the AI-Driven Retinal Screening Device Market. Governments and public health organizations are prioritizing early detection of eye diseases to reduce avoidable blindness and healthcare costs. According to the World Health Organization (WHO), integrated people-centered eye care is essential to achieving universal health coverage, encouraging eye screening at the primary healthcare level.
AI-powered retinal screening devices enable non-specialist healthcare professionals to perform rapid eye examinations, making screening accessible in community clinics, pharmacies, and mobile health units. The National Eye Institute (NEI) reports that diabetic retinopathy often develops without early symptoms, highlighting the importance of routine screening.
Portable fundus cameras combined with AI software allow healthcare providers to screen large populations efficiently while referring only high-risk patients to ophthalmologists. Government-funded telemedicine initiatives are also expanding digital healthcare infrastructure, particularly in rural areas. As aging populations and diabetes prevalence continue to rise globally, demand for scalable, cost-effective AI-based retinal screening solutions is expected to increase, creating substantial long-term growth opportunities for technology providers and healthcare institutions.
Conclusion
The global AI-Driven Retinal Screening Device Market is poised for strong growth, driven by the increasing prevalence of diabetes, rising awareness of early eye disease detection, and expanding adoption of artificial intelligence in healthcare. AI-enabled screening solutions improve diagnostic accuracy, reduce screening time, and enhance access to retinal care, particularly in underserved regions. Continued regulatory support, teleophthalmology initiatives, and investments in digital healthcare infrastructure are expected to accelerate adoption. As healthcare systems prioritize preventive eye care and scalable diagnostic technologies, AI-driven retinal screening devices are likely to play an increasingly important role in reducing preventable vision loss and improving patient outcomes worldwide.
Top comments (0)